产品名称

E 3810 dihydrochloride - AL 3810 dihydrochloride | Lucitanib

产品货号

Axon 1942 CAS [N.A.] MF C26H25N3O4.2HClMW 516.42 Purity: 99% Soluble in water and DMSO Description First-in-class dual VEGFR/FGFR tyrosine kinase inhibitor; E-3810 potently and selectively inhibited VEGFR1, -2, and -3 and FGFR-1 and -2 kinases in the nanomolar range; a potent antiangiogenic small molecule with a favorable pharmacokinetic profile and broad spectrum antitumor activity References Certificates Categories Extra info E Bello et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011, 71(4), 1396-1405. JC Soria et al. First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors. Ann. Oncol. 2011, 22, 40. Y Zhou et al. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR. J. Cell Mol. Med. 2012, 16(10), 2321-2330. G Damia et al. Is PDGFR an important target for E-3810? J. Cell Mol. Med. 2012, 16(11), 2838-2839. [Letter to the Editor] Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology VEGFR RTK class IV and V; EC 2.7.10.1 FGFR Dual VEGFR/FGFR tyrosine kinase inhibitor Chemical name 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide dihydrochloride Parent CAS No. [1058137-23-7] Order Size Unit Price Stock 2 mg €95.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

E 3810 dihydrochloride - AL 3810 dihydrochloride | Lucitanib

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 1942

CAS [N.A.]

MF C26H25N3O4.2HCl
MW 516.42

Purity: 99%
Soluble in water and DMSO

E 3810 dihydrochloride

Description

First-in-class dual VEGFR/FGFR tyrosine kinase inhibitor; E-3810 potently and selectively inhibited VEGFR1, -2, and -3 and FGFR-1 and -2 kinases in the nanomolar range; a potent antiangiogenic small molecule with a favorable pharmacokinetic profile and broad spectrum antitumor activity